ANGO

MKT CAP:$457M

AngioDynamics, Inc.

Market Cap

$457M

Healthcare·Medical - Instruments & Supplies·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$11.10-$1.58 (-12.46%)

Apr 24, 2026

Company Details

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology a...

CEO

James C. Clemmer

IPO Date

Jun 1, 2004

Website

www.angiodynamics.com

Key Metrics TTM

Revenue

$314M

+10.7% YoY

Net Income

-$31M

EPS (Diluted)

-$0.75

Free Cash Flow

$2M

Revenue / Share

$7.54

Gross Margin

53.5%

Operating Margin

-8.1%

Net Margin

-10.0%

FCF Margin

0.5%

P/S

1.5x

P/E

—

Earnings Reports

Q3 2026

Apr 2, 2026

$78M+8.9%EPS -$0.19

Q2 2026

Jan 6, 2026

$79M+9.0%EPS -$0.15

Q1 2026

Oct 2, 2025

$76M+12.2%EPS -$0.26

FY 2025

Jul 18, 2025

$292M-3.8%EPS -$0.83

Q4 2025

Jul 18, 2025

$80M+12.9%EPS -$0.15

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 22	$87M	$46M	-$6M
Q1 23	$82M	$42M	-$13M
Q2 23	$85M	$45M	-$8M
Q3 23	$81M	$41M	-$9M
Q4 23	$91M	$46M	-$21M
Q1 24	$79M	$40M	$35M
Q2 24	$79M	$40M	-$13M
Q3 24	$75M	$36M	-$200M
Q4 24	$71M	$39M	-$14M
Q1 25	$67M	$37M	-$13M
Q2 25	$73M	$40M	-$11M
Q3 25	$72M	$39M	-$10M
Q4 25	$80M	$42M	-$6M
Q1 26	$76M	$42M	-$11M
Q2 26	$79M	$42M	-$2M
Q3 26	$78M	$41M	-$6M

Valuation

Quarter	P/S	P/E
Q4 22	2.6x	—
Q1 23	2.7x	—
Q2 23	1.5x	—
Q3 23	1.5x	—
Q4 23	1.2x	—
Q1 24	0.9x	49.4x
Q2 24	0.8x	—
Q3 24	0.7x	—
Q4 24	0.9x	—
Q1 25	1.0x	—
Q2 25	1.0x	—
Q3 25	1.3x	—
Q4 25	1.4x	—
Q1 26	1.3x	—
Q2 26	1.7x	—
Q3 26	1.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	$9M	$8M
Q1 23	-$25M	-$26M
Q2 23	$7M	$7M
Q3 23	$1M	$164.0K
Q4 23	$16M	$14M
Q1 24	-$26M	-$27M
Q2 24	$5M	$5M
Q3 24	-$13M	-$16M
Q4 24	$5M	$4M
Q1 25	-$18M	-$19M
Q2 25	$2M	$2M
Q3 25	-$13M	-$15M
Q4 25	$19M	$18M
Q1 26	-$16M	-$17M
Q2 26	$5M	$4M
Q3 26	-$3M	-$4M

Capital Expenditures

Quarter	CapEx
Q4 22	$1M
Q1 23	$1M
Q2 23	$741.0K
Q3 23	$1M
Q4 23	$2M
Q1 24	$791.0K
Q2 24	$554.0K
Q3 24	$4M
Q4 24	$566.0K
Q1 25	$1M
Q2 25	$797.0K
Q3 25	$2M
Q4 25	$777.0K
Q1 26	$731.0K
Q2 26	$422.0K
Q3 26	$1M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	+13.2%	-5.1%
Q1 23	+5.9%	+11.5%
Q2 23	+9.1%	+7.6%
Q3 23	+9.1%	+13.1%
Q4 23	+4.7%	+19.8%
Q1 24	-3.5%	-54.0%
Q2 24	-7.4%	-1.4%
Q3 24	-6.9%	+206.9%
Q4 24	-22.1%	-23.7%
Q1 25	-14.2%	+84.6%
Q2 25	-7.9%	-9.0%
Q3 25	-4.2%	-70.2%
Q4 25	+12.9%	+0.6%
Q1 26	+12.2%	+7.2%
Q2 26	+9.0%	-2.4%
Q3 26	+8.9%	+3.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$3M	3.3%
Q1 23	$3M	3.7%
Q2 23	$3M	3.9%
Q3 23	$2M	2.2%
Q4 23	$3M	3.3%
Q1 24	$4M	5.3%
Q2 24	$2M	2.4%
Q3 24	$3M	3.5%
Q4 24	$2M	2.7%
Q1 25	$3M	4.7%
Q2 25	$3M	3.5%
Q3 25	$2M	3.3%
Q4 25	$2M	2.0%
Q1 26	$4M	5.9%
Q2 26	$3M	3.6%
Q3 26	$3M	3.4%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 22	$8M	$11M	$27M
Q1 23	$8M	$10M	$27M
Q2 23	$7M	$11M	$26M
Q3 23	$7M	$9M	$25M
Q4 23	$8M	$10M	$26M
Q1 24	$8M	$11M	$27M
Q2 24	$9M	$9M	$25M
Q3 24	$8M	$11M	$25M
Q4 24	$7M	$10M	$25M
Q1 25	$6M	$11M	$26M
Q2 25	$6M	$10M	$26M
Q3 25	$7M	$10M	$26M
Q4 25	$7M	$10M	$26M
Q1 26	$6M	$13M	$28M
Q2 26	$8M	$10M	$27M
Q3 26	$7M	$11M	$27M

Revenue Segments

Quarter	Med Device	Med Tech
Q4 22	$64M	$23M
Q1 24	$53M	$26M
Q2 24	$54M	$25M
Q3 24	$49M	$26M
Q4 24	$42M	$29M
Q1 25	$40M	$28M
Q2 25	$41M	$32M
Q3 25	$41M	$31M
Q2 26	$44M	$36M
Q3 26	$41M	$37M

Revenue by Geography

Quarter	Non-US	United States
Q1 24	$14M	$64M
Q2 24	$15M	$64M
Q3 24	$13M	$62M
Q1 25	$8M	$59M
Q2 25	$10M	$63M
Q3 25	$11M	$61M
Q2 26	$12M	$68M
Q3 26	$11M	$67M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$29M	$0	$29M
Q1 23	$25M	$0	$25M
Q2 23	$30M	$0	$30M
Q3 23	$30M	$0	$30M
Q4 23	$45M	$0	$45M
Q1 24	$58M	$0	$58M
Q2 24	$61M	$0	$61M
Q3 24	$78M	$0	$78M
Q4 24	$76M	$0	$76M
Q1 25	$55M	$0	$55M
Q2 25	$54M	$0	$54M
Q3 25	$45M	$0	$45M
Q4 25	$56M	$0	$56M
Q1 26	$39M	$0	$39M
Q2 26	$42M	$0	$42M
Q3 26	$38M	$0	$38M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 22	39M	+0.2%	+1.6%
Q1 23	39M	+0.4%	+1.5%
Q2 23	39M	+0.5%	+1.1%
Q3 23	40M	+0.0%	+1.1%
Q4 23	40M	+0.3%	+1.1%
Q1 24	40M	+0.9%	+1.7%
Q2 24	40M	+0.6%	+1.8%
Q3 24	40M	+0.0%	+1.8%
Q4 24	40M	+0.5%	+2.1%
Q1 25	41M	+0.6%	+1.7%
Q2 25	41M	+0.7%	+1.7%
Q3 25	41M	-0.2%	+1.5%
Q4 25	41M	+0.3%	+1.4%
Q1 26	41M	+0.5%	+1.3%
Q2 26	41M	+0.6%	+1.2%
Q3 26	42M	+0.5%	+1.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 22	$114.5K	760
Q1 23	$107.3K	760
Q2 23	$112.4K	760
Q3 23	$106.2K	760
Q4 23	$111.7K	815
Q1 24	$96.5K	815
Q2 24	$97.0K	815
Q3 24	$92.2K	815
Q4 24	$94.9K	748
Q1 25	$90.2K	748
Q2 25	$97.4K	748
Q3 25	$96.3K	748
Q4 25	$118.8K	675
Q1 26	$112.2K	675
Q2 26	$117.7K	675
Q3 26	$116.2K	675

Revenue / Employee